N-{6-[(7S,9aS)-7-(hydroxymethyl)-octahydropyrazino[2,1-c][1,4]oxazin-8-yl]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl}-2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethylpropanamide
概述 用途与合成方法 MSDS N-{6-[(7S,9aS)-7-(hydroxymethyl)-octahydropyrazino[2,1-c][1,4]oxazin-8-yl]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl}-2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethylpropanamide价格(试剂级) 上下游产品信息
| 中文名称 | N-{6-[(7S,9aS)-7-(hydroxymethyl)-octahydropyrazino[2,1-c][1,4]oxazin-8-yl]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl}-2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethylpropanamide |
|---|---|
| 中文同义词 | GSK1144814A;ELINZANETANT ; GSK1144814A ; NT-814 ; NT 814 ; NT814 ; GSK-1144814A ; GSK 1144814A;依林奈坦;化合物ELINZANETANT;2-(3,5-双(三氟甲基)苯基)-N-(4-(4-氟-2-甲基苯基)-6-((7S,9AS)-7-(羟甲基)六氢吡嗪并[2,1-C][1,4]恶嗪-8(1H)-基)吡啶-3-基)-N,2-二甲基丙酰胺;依林唑坦;化合物ELINZANETANT,10 MM DMSO 溶液;N-[4-(4-氟-2-甲基苯基)-6-[(7S,9aS)-六氢-7-(羟基甲基)吡嗪并[2,1-c][1,4]恶嗪-8(1H)-基]-3-吡啶基]-N,α,α-三甲基-3,5-双(三氟甲基)苯乙酰胺 |
| 英文名称 | Elinzanetant |
| 英文同义词 | N-{6-[(7S,9aS)-7-(hydroxymethyl)-octahydropyrazino[2,1-c][1,4]oxazin-8-yl]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl}-2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethylpropanamide;Benzeneacetamide, N-[4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-hexahydro-7-(hydroxymethyl)pyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl]-N,α,α-trimethyl-3,5-bis(trifluoromethyl)-;Elinzanetant;NT 814;NT814;NT-814;2-[3,5-bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]pyridin-3-yl}-N,2-dimethylpropanamide;inhibit,BAY3427080,Elinzanetant,BAY-3427080,Inhibitor,Tachykinin receptor,NT-814,NT814,NK receptor,Neurokinin Receptor,NT 814,BAY 3427080 |
| CAS号 | 929046-33-3 |
| 分子式 | C33H35F7N4O3 |
| 分子量 | 668.66 |
| EINECS号 | 629-865-8 |
| 相关类别 | 小分子抑制剂;医药原料 |
| Mol文件 | 929046-33-3.mol |
| 结构式 | ![N-{6-[(7S,9aS)-7-(hydroxymethyl)-octahydropyrazino[2,1-c][1,4]oxazin-8-yl]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl}-2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethylpropanamide 结构式](CAS/20200401/GIF/929046-33-3.gif) |
N-{6-[(7S,9aS)-7-(hydroxymethyl)-octahydropyrazino[2,1-c][1,4]oxazin-8-yl]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl}-2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethylpropanamide 性质
| 沸点 | 672.1±55.0 °C(Predicted) |
|---|---|
| 密度 | 1.40±0.1 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | DMSO：100 mg/mL（149.56 mM；需要超声波） |
| 酸度系数(pKa) | 14.57±0.10(Predicted) |
| 形态 | 固体 |
| 颜色 | 白色至浅黄色 |
| InChIKey | DWRIJNIPBUFCQS-NCTSPAQWNA-N |
| SMILES | N(C1=CN=C(N2C[C@@]3([H])COCCN3C[C@H]2CO)C=C1C1C=CC(F)=CC=1C)(C)C(=O)C(C1C=C(C(F)(F)F)C=C(C(F)(F)F)C=1)(C)C |&1:7,15,r| |
N-{6-[(7S,9aS)-7-(hydroxymethyl)-octahydropyrazino[2,1-c][1,4]oxazin-8-yl]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl}-2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethylpropanamide 用途与合成方法
Elizanetant (NT-814) 是一种具有口服活性的、选择性 NK-1,3 受体拮抗剂，Elizanetant 可用于血管舒缩和精神分裂症研究。
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025/12/22 | HY-109171 | Elinzanetant | 929046-33-3 | 1 mg | 940元 |
| 2025/12/22 | HY-109171 | N-{6-[(7S,9aS)-7-(hydroxymethyl)-octahydropyrazino[2,1-c][1,4]oxazin-8-yl]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl}-2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethylpropanamide Elinzanetant | 929046-33-3 | 5 mg | 2500元 |